TickerFacts.

RxSight, Inc. (RXST): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$44.92M
Year ended 2025-12-31
-$51.58M
Trailing 12 months to 2026-06-30
2020-12-31: -$31.56M2021-12-31: -$48.81M2022-12-31: -$59.43M2023-12-31: -$46.01M2024-12-31: -$33.28M2025-12-31: -$44.92M-$44.92M
2020-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$44.92Mn/m2026-02-25, From 2025-01-01
2024-12-31-$33.28Mn/m2026-02-25, From 2024-01-01
2023-12-31-$46.01Mn/m2026-02-25, From 2023-01-01
2022-12-31-$59.43Mn/m2025-02-25, From 2022-01-01
2021-12-31-$48.81Mn/m2023-03-06, From 2021-01-01
2020-12-31-$31.56Mn/a2022-03-08, From 2020-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Ophthalmic Goods), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
RxSight, Inc. (RXST)2025-12-31-$44.92Mn/m
Warby Parker Inc. (WRBY)2025-12-31$44.94M+185.3%
National Vision Holdings, Inc. (EYE)2026-01-03$149.98M+85.2%
Cooper Companies, Inc. (COO)2025-10-31$1.06B-1.9%
Bausch & Lomb Corp (BLCO)2025-12-31$534.00M-10.7%

Compare RXST, WRBY, EYE, COO side by side · Screen every company in Ophthalmic Goods ↗